


## Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 were \$19.7 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com).


## Cash and Operating Income

(USD m)




## 12 Month Stock Performance (as of November 18)

■ Teva ■ (DRG) NYSE Pharma Index




## Net Revenues

(USD m)




## Net Income (non GAAP<sup>1</sup>)

(USD m)




## Earnings Per Share (non GAAP<sup>1</sup>)

(USD)



## Dividends Per Share

(USD)





(1) See non GAAP reconciliation in our report for the 3<sup>th</sup> Quarter 2016

## Teva Completes Acquisition of Actavis Generics: August 2, 2016

Acquisition reinforces Teva's strategy and opens new possibilities for the company in generics and specialty; serving 250 million people, every day.

### Revenues by Markets and Segments


Q3 - 2016



\* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, manufacturing services of divested products, and sales of medical devices

### Profit\*\* by Segment

Q3 - 2016



\*\* Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

### Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	TV-45070 Topical Neuropathic pain	TEV-48125 (anti CGRP) Chronic and episodic migraine (Global)	Vantrela ER (hydrocodone bitartrate) Chronic Pain (U.S.)
TEV-90105 (abuse deterrent) Pain	Fasinumab** Chronic Lower Back Pain	TEV-48125 (anti CGRP) Cluster Headache (Global)	TEV-90109 Opioid addiction
SD-809 (deutetrabenazine) Tourette syndrome	Laquinimod Multiple sclerosis (primary progressive)	TV-46763 (abuse deterrent) Pain	Copaxone® 40mg (glatirameracetate) Multiple sclerosis (Growth markets)
SD-1077 (deulevodopa) Parkinson's Disease	Laquinimod Huntington disease	Fasinumab** Osteoarthritis pain	SD-809 (deutetrabenazine) Huntington Disease
TV-46000 Schizophrenia	Pridopidine Huntington disease	Laquinimod Multiple sclerosis (relapsing remitting)	Reslizumab*IV Asthma (Global)
TEV-48107 (tidal inhaler) COPD		SD-809 (deutetrabenazine) Tardive dyskinesia	Fluticasone Propionate RespiClick® Asthma (U.S.)
Fluticasone Salmeterol Spiromax® Asthma (EU)		QVAR® (beclomethasonedipropionateBAI) Asthma (U.S.)	Fluticasone Salmeterol RespiClick® Asthma (U.S.)
TEV-48107 (tidal inhaler) COPD		Reslizumab*SC Asthma (Global)	
TVB018 Biosimilar		CT-P10*** Biosimilar (Rituxan)	
		CT-P6 *** Biosimilar (Herceptin)	

- Migraine & Pain - 9
- Neurology & psychiatry - 10
- Respiratory - 7
- Biosimilars - 3

29 products in phase 1 through submission;  
More than 20 submissions in 2016-2021

Note: Pipeline is current as of Oct 20, 2016. Phase 1 includes also projects designated for IND filing.

\* Approved in the U.S under the trade name: CINQAIR® \*\*In partnership with Regeneron \*\*\* In partnership with Celltrion